U

University of California, San Diego | UCSD Moores Cancer Center

Research site
(Unclaimed)
Location
3855 Health Sciences Drive, La Jolla, California, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab
Gemcitabine
Nivolumab
Ibrutinib
Palbociclib
Cetuximab
Paclitaxel
BMS-936558
Obinutuzumab
Lenalidomide

Parent organization

This site is a part of University of California, San Diego

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 90 total trials

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma a...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

We hypothesize that GA101 - Obinutuzumab in combination with HDMP is well tolerated and will induce similar if not higher response rates than the one...

Active, not recruiting
CLL
Drug: GA101/HDMP

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus t...

Active, not recruiting
Breast Cancer
Drug: 5-Fluorouracil
Drug: Trastuzumab

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in...

Enrolling
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Endometrial Cancer
Biological: vudalimab

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling
Melanoma
Solid Tumor, Adult
Drug: KIN-2787 and binimetinib
Drug: KIN-2787

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cance...

Enrolling
Ovarian Neoplasms
NSCLC, Recurrent
Diagnostic Test: xT CDx with HLA-LOH Assay
Biological: A2B694
Locations recently updated

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036...

Enrolling
Advanced Solid Tumors
Colorectal Cancer
Drug: Inavolisib
Drug: Atezolizumab

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tusp...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Po...

Active, not recruiting
Relapsed/Refractory Multiple Myeloma
Drug: Ixazomib
Drug: Dexamethasone

The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with...

Active, not recruiting
Squamous Cell Carcinoma of the Head and Neck
Drug: Pembrolizumab

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib s...

Invitation-only
Solid Tumor
Graft Vs Host Disease
Drug: Ibrutinib

The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL. This st...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: ibrutinib
Drug: GA101

Lung cancer is the leading cause of cancer deaths. Advances in the systemic treatment of non-small cell lung cancer (NSCLC) have increased survival i...

Active, not recruiting
Lung Cancer
Drug: Osimertinib
Drug: Abemaciclib

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib...

Active, not recruiting
Breast Cancer
Drug: Standard Adjuvant Endocrine Therapy
Drug: Palbociclib

This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembro...

Active, not recruiting
Hypopharynx Cancer
Nasopharynx Cancer
Drug: Pembrolizumab, Cetuximab

This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemorad...

Active, not recruiting
Laryngeal Cancer
Squamous Cell Carcinoma
Drug: pembrolizumab (MK-3475)
Drug: Cisplatin

This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion p...

Enrolling
Skin Kaposi Sarcoma
Behavioral: Quality-of-Life Assessment
Other: Laboratory Biomarker Analysis

The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM fo...

Active, not recruiting
Glioblastoma
Glioma
Drug: Dendritic cell immunotherapy

This is an open-label, randomized, phase II trial to test the efficacy of Ibrutinib in combination with either Nivolumab or Cetuximab in the treatmen...

Active, not recruiting
Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Drug: Nivolumab
Drug: Ibrutinib 560mg PO daily (Imbruvica)

Trial sponsors

University of California San Diego logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
Pfizer logo
Roche logo
A
Genentech logo
D
M
J

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems